- Home
- DATS vs DWTX Comparison
DATS vs DWTX Comparison
Compare DATS & DWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- DWTX
- Stock Information
- Founded
- DATS 2014
- DWTX 2012
- Country
- DATS United States
- DWTX United States
- Employees
- DATS N/A
- DWTX N/A
- Industry
- DATS Computer Software: Prepackaged Software
- DWTX
- Sector
- DATS Technology
- DWTX
- Exchange
- DATS Nasdaq
- DWTX NYSE
- Market Cap
- DATS 10.4M
- DWTX 9.2M
- IPO Year
- DATS 2021
- DWTX N/A
- Fundamental
- Price
- DATS $2.60
- DWTX $4.82
- Analyst Decision
- DATS
- DWTX Strong Buy
- Analyst Count
- DATS 0
- DWTX 1
- Target Price
- DATS N/A
- DWTX $10.00
- AVG Volume (30 Days)
- DATS 373.1K
- DWTX 40.7K
- Earning Date
- DATS 08-13-2025
- DWTX 08-14-2025
- Dividend Yield
- DATS N/A
- DWTX N/A
- EPS Growth
- DATS N/A
- DWTX N/A
- EPS
- DATS N/A
- DWTX N/A
- Revenue
- DATS $388.00
- DWTX N/A
- Revenue This Year
- DATS N/A
- DWTX N/A
- Revenue Next Year
- DATS N/A
- DWTX N/A
- P/E Ratio
- DATS N/A
- DWTX N/A
- Revenue Growth
- DATS N/A
- DWTX N/A
- 52 Week Low
- DATS $1.01
- DWTX $1.62
- 52 Week High
- DATS $9.34
- DWTX $29.28
- Technical
- Relative Strength Index (RSI)
- DATS 48.99
- DWTX N/A
- Support Level
- DATS $2.54
- DWTX N/A
- Resistance Level
- DATS $2.80
- DWTX N/A
- Average True Range (ATR)
- DATS 0.26
- DWTX 0.00
- MACD
- DATS -0.02
- DWTX 0.00
- Stochastic Oscillator
- DATS 12.39
- DWTX 0.00
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts.
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.